Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 12Endometrial Hyperplasia 4Turcot syndrome 1Overweight 1Obesity 1Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Adenocarcinoma 1Carcinoma, Endometrioid 1Advanced, Persistent, or Recurrent Endometrial Cancer 1

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2sintilimab 1serabelisib 1sapanisertib 1rucaparib 1pembrolizumab 1palbociclib 1olaparib 1durvalumab 1ceralasertib 1adavosertib 1Therapeutics 1Restraint, Physical 1Radiation, Ionizing 1Radiation 1Platinum 1Paclitaxel 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Fulvestrant 1Congresses as Topic 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Endometrioid × Medroxyprogesterone Acetate × Gynecologic × Clear all
NCT06549855 2024-08-12

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Peking University People's Hospital

Phase NA Not yet recruiting
10 enrolled
Gynecologic

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡